Patient perspectives on buprenorphine/naloxone for chronic noncancer pain: A qualitative interview study.

IF 2.1 Q3 CLINICAL NEUROLOGY
Katelyn Halpape, Derek Jorgenson, Marla Rogers
{"title":"Patient perspectives on buprenorphine/naloxone for chronic noncancer pain: A qualitative interview study.","authors":"Katelyn Halpape, Derek Jorgenson, Marla Rogers","doi":"10.1080/24740527.2026.2627924","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Buprenorphine/naloxone (Suboxone) is an emerging option for chronic noncancer pain (CNCP), but evidence on transitioning patients from full opioid agonists remains limited. At the University of Saskatchewan Chronic Pain Clinic (UCPC) in Saskatchewan, Canada, pharmacists support these transitions within a unique interdisciplinary model.</p><p><strong>Aim: </strong>The aim of this study was to explore patient perspectives on transitioning to and using buprenorphine/naloxone for CNCP.</p><p><strong>Methods: </strong>This qualitative study involved one-on-one semistructured interviews with current and former UCPC patients who had transitioned to buprenorphine/naloxone for CNCP. Participants were invited by email to complete semistructured interviews via Zoom or telephone with a trained facilitator. The interview guide was informed by a literature review and pretested. Recorded interviews were transcribed using an artificial intelligence-supported platform, reviewed for accuracy, and analyzed in NVivo 14 using thematic analysis.</p><p><strong>Results: </strong>Seven participants (five females, two males; average age 57 years) were interviewed. Most had used opioids long term for pain prior to transition. Experiences varied: some transitioned easily, whereas others required more time or experienced discomfort. Buprenorphine/naloxone tablet size and taste were the most common negative experiences. Side effects were mild (e.g. drowsiness, constipation). Some expressed concern about long-term use and desired clearer communication during transitions. Although buprenorphine/naloxone was not uniformly experienced as effective for pain relief, most would recommend buprenorphine/naloxone to others.</p><p><strong>Conclusion: </strong>Patient experiences at UCPC suggest that though buprenorphine/naloxone is not a universal solution for CNCP, it may be an effective option for carefully selected individuals. Side effects were tolerable, and most would recommend the treatment. Improved communication during transitions may enhance patient experiences.</p>","PeriodicalId":53214,"journal":{"name":"Canadian Journal of Pain-Revue Canadienne de la Douleur","volume":"10 1","pages":"2627924"},"PeriodicalIF":2.1000,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13022992/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Pain-Revue Canadienne de la Douleur","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/24740527.2026.2627924","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Buprenorphine/naloxone (Suboxone) is an emerging option for chronic noncancer pain (CNCP), but evidence on transitioning patients from full opioid agonists remains limited. At the University of Saskatchewan Chronic Pain Clinic (UCPC) in Saskatchewan, Canada, pharmacists support these transitions within a unique interdisciplinary model.

Aim: The aim of this study was to explore patient perspectives on transitioning to and using buprenorphine/naloxone for CNCP.

Methods: This qualitative study involved one-on-one semistructured interviews with current and former UCPC patients who had transitioned to buprenorphine/naloxone for CNCP. Participants were invited by email to complete semistructured interviews via Zoom or telephone with a trained facilitator. The interview guide was informed by a literature review and pretested. Recorded interviews were transcribed using an artificial intelligence-supported platform, reviewed for accuracy, and analyzed in NVivo 14 using thematic analysis.

Results: Seven participants (five females, two males; average age 57 years) were interviewed. Most had used opioids long term for pain prior to transition. Experiences varied: some transitioned easily, whereas others required more time or experienced discomfort. Buprenorphine/naloxone tablet size and taste were the most common negative experiences. Side effects were mild (e.g. drowsiness, constipation). Some expressed concern about long-term use and desired clearer communication during transitions. Although buprenorphine/naloxone was not uniformly experienced as effective for pain relief, most would recommend buprenorphine/naloxone to others.

Conclusion: Patient experiences at UCPC suggest that though buprenorphine/naloxone is not a universal solution for CNCP, it may be an effective option for carefully selected individuals. Side effects were tolerable, and most would recommend the treatment. Improved communication during transitions may enhance patient experiences.

患者对丁丙诺啡/纳洛酮治疗慢性非癌性疼痛的看法:一项定性访谈研究。
背景:丁丙诺啡/纳洛酮(Suboxone)是慢性非癌性疼痛(CNCP)的一种新兴选择,但关于患者从完全阿片类激动剂过渡的证据仍然有限。在加拿大萨斯喀彻温省的萨斯喀彻温大学慢性疼痛诊所(UCPC),药剂师在一个独特的跨学科模式中支持这些转变。目的:本研究的目的是探讨患者对过渡到丁丙诺啡/纳洛酮治疗CNCP的看法。方法:本定性研究采用一对一的半结构化访谈,访谈对象为目前和曾经的UCPC患者,这些患者已改用丁丙诺啡/纳洛酮治疗CNCP。参与者通过电子邮件被邀请通过Zoom或电话与训练有素的调解人完成半结构化访谈。面试指南是通过文献综述和预测试来了解的。记录的访谈使用人工智能支持的平台进行转录,审查准确性,并在NVivo 14中使用主题分析进行分析。结果:7名参与者(5名女性,2名男性,平均年龄57岁)被采访。大多数人在过渡之前长期使用阿片类药物治疗疼痛。经历各不相同:一些人很容易过渡,而另一些人则需要更多的时间或经历不适。丁丙诺啡/纳洛酮片剂的大小和口味是最常见的负面体验。副作用轻微(如嗜睡、便秘)。一些人对长期使用表示关注,并希望在过渡期间有更清晰的沟通。虽然丁丙诺啡/纳洛酮在缓解疼痛方面的效果并不一致,但大多数人会向其他人推荐丁丙诺啡/纳洛酮。结论:UCPC的患者经验表明,虽然丁丙诺啡/纳洛酮不是CNCP的通用解决方案,但对于精心挑选的个体可能是一种有效的选择。副作用是可以忍受的,大多数人会推荐这种治疗方法。在过渡期间改善沟通可以提高病人的体验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
12.50%
发文量
36
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书